Get the Stockscreener App
2.36
4.45%
-0.11
Pre-market:
2.33
-0.03
-1.27%
Biovie Inc stock is traded at $2.36, with a volume of 2.65M.
It is down -4.45% in the last 24 hours and down -14.49% over the past month.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
See More
Previous Close:
$2.47
Open:
$2.55
24h Volume:
2.65M
Relative Volume:
0.45
Market Cap:
$41.93M
Revenue:
-
Net Income/Loss:
$-43.27M
P/E Ratio:
-2.0171
EPS:
-1.17
Net Cash Flow:
$-41.11M
1W Performance:
+8.26%
1M Performance:
-14.49%
6M Performance:
-42.45%
1Y Performance:
-81.56%
1-Day Range:
$2.2201
$2.55
1-Week Range:
$2.12
$2.5764
52-Week Range:
$1.0404
$33.10
Biovie Inc Stock (BIVI) Company Profile
Name
Biovie Inc
Sector
Industry
Phone
775-888-3162
Address
680 W NYE LANE, CARSON CITY
Compare BIVI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIVI
Biovie Inc
|
2.36 | 41.93M | 0 | -43.27M | -41.11M | -1.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.11 | 106.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.59 | 80.61B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
649.26 | 38.82B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
240.55 | 31.03B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
122.15 | 29.28B | 3.30B | -501.07M | 1.03B | -2.1146 |
Biovie Inc Stock (BIVI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-22-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-15-21 | Initiated | B. Riley Securities | Buy |
Biovie Inc Stock (BIVI) Latest News
BioVie Inc. (BIVI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - AccessWire
Bronstein, Gewirtz & Grossman, LLC Is Investigating BioVie Inc. (BIVI) And Encourages Investors to Connect - Stockhouse Publishing
BIOVIE ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
BIOVIE, INC. CLASS ACTION ALERT: Biovie, Inc. Class Action Alert: Wolf Haldenstein Adler Freeman & Herz LLP Announces That a Class Action Lawsuit Has Been Filed In The United States District Court for The District of Nevada Against Biovie, Inc. - AccessWire
2025-01-02 | Bronstein, Gewirtz & Grossman, LLC Encourages BioVie Inc. (BIVI) Stockholders to Inquire about Securities Investigation | NDAQ:BIVI | Press Release - Stockhouse Publishing
Bronstein, Gewirtz & Grossman, LLC Encourages BioVie Inc. (BIVI) Stockholders to Inquire about Securities Investigation - AccessWire
BioVie Leaders Sued for Stock Slips on Clinical Trial Misconduct - Bloomberg Law
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against BioVie Inc. (BIVI) and Encourages Investors to Learn More About the Investigation - AccessWire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against BioVie Inc. (BIVI) And Encourages Investors to Reach Out - AccessWire
Certain Common Stock of BioVie Inc. are subject to a Lock-Up Agreement Ending on 24-DEC-2024. - Marketscreener.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against BioVie Inc. (BIVI) And Encourages Stockholders to Reach Out - AccessWire
Bronstein, Gewirtz & Grossman, LLC Is Investigating BioVie Inc. (BIVI) And Encourages Stockholders to Connect - AccessWire
BioVie Inc. (BIVI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - AccessWire
2024-12-15 | BioVie Inc. (BIVI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | NDAQ:BIVI | Press Release - Stockhouse Publishing
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against BioVie Inc. (BIVI) and Encourages Stockholders to Learn More About the Investigation - AccessWire
Ascites Treatment Market 2034: EMA, PDMA, FDA Approvals, Medication, Prevalence, Therapies, Clinical Trials and Companies by DelveInsight - The Globe and Mail
SEC goes after David Banister and The Market Analysts Group - FX News Group
SEC Sues Investment Advisor Over $1.4 Million Pump-and-Dump Scheme Involving BioVie Stock - USA Herald
SEC Accuses Investment Advisor of $1.4M Pump-and-Dump Scheme Involving BioVie Inc. - USA Herald
Biovie Inc. to Present Design of Planned Phase 2 Study of Bezisterim for the Treatment of Long Covid At Theemystifying Long Covid International Conference - Marketscreener.com
BioVie to Present Design of Planned Phase 2 Study of Bezisterim for the Treatment of Long COVID at the Demystifying Long COVID International Conference - The Manila Times
BioVie to Present Design of Planned Phase 2 Study of - GlobeNewswire
BioVie's Long COVID Drug Trial Gets Pentagon Backing; Phase 2 Study to Include 200 Patients | BIVI Stock News - StockTitan
BioVie shareholders approve board nominees and equity plan expansion By Investing.com - Investing.com Canada
BioVie shareholders approve board nominees and equity plan expansion - Investing.com India
BioVie’s Upcoming Parkinson’s Disease Clinical Trial is Fully Funded - GlobeNewswire
BioVie's Upcoming Parkinson's Disease Clinical Trial is Fully Funded - The Manila Times
BioVie Raises Capital Through Direct Stock Offering - MSN
BioVie Inc. Announces Closing of Registered Direct Offering - GlobeNewswire
BioVie Raises $3.24 Million in Direct Offering - TipRanks
BioVie sets price for $3.2 million stock offering By Investing.com - Investing.com Australia
BioVie prices stock offering at $2.83 per share By Investing.com - Investing.com Canada
BIVIBioVie, Inc. Latest Stock News & Market Updates - StockTitan
BioVie prices stock offering at $2.83 per share - Investing.com
UPDATE -- BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - The Manila Times
BioVie sets price for $3.2 million stock offering - Investing.com India
BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - The Manila Times
Short Interest in BioVie Inc. (NASDAQ:BIVI) Decreases By 51.0% - MarketBeat
BioVie Inc. Announces Pricing of Registered Direct Offering and Concurrent Private Placement Carson City, Nevada, October 23, 2024 — BioVie Inc. (NASDAQ: BIVI), a clinical-stage company focused on developing innovative drug therapies for ch - Defense World
BioVie Inc. Announces Closing of Registered Direct Offering and Concurrent Private Placement - The Manila Times
BioVie Raises $6 Million in Strategic Funding - TipRanks
BioVie Announces $6 Million Stock Offering and Placement - TipRanks
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
BioVie announces $6 million stock offering and warrants By Investing.com - Investing.com Australia
BioVie announces $6 million stock offering and warrants - Investing.com India
BioVie Inc. Announces Pricing of Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules - The Manila Times
BioVie 2.667M share registered direct offering priced at $2.25 - TipRanks
Biovie Inc Stock (BIVI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.08%
0.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):